82_FR_47951 82 FR 47754 - Center for Scientific Review; Notice of Closed Meetings

82 FR 47754 - Center for Scientific Review; Notice of Closed Meetings

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 82, Issue 197 (October 13, 2017)

Page Range47754-47755
FR Document2017-22139

Federal Register, Volume 82 Issue 197 (Friday, October 13, 2017) 
[Federal Register Volume 82, Number 197 (Friday, October 13, 2017)]
[Notices]
[Pages 47754-47755]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2017-22139]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Center for Scientific Review; Notice of Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: Center for Scientific Review Special Emphasis 
Panel; Immune System Plasticity in Dental, Oral, and Craniofacial 
Diseases.
    Date: November 1, 2017.
    Time: 2:00 p.m. to 6:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, 6701 Rockledge Drive, 
Bethesda, MD 20892 (Virtual Meeting).
    Contact Person: Yi-Hsin Liu, Ph.D., Scientific Review Officer, 
Center for Scientific Review, National Institutes of Health, 6701 
Rockledge Drive, Room 4214, MSC 7814, Bethesda, MD 20892, 301-435-
1781, [email protected].

    Name of Committee: Center for Scientific Review Special Emphasis 
Panel; PAR-17-263: Innovation for HIV Vaccine Discovery.
    Date: November 3, 2017.
    Time: 10:00 a.m. to 5:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, 6701 Rockledge Drive, 
Bethesda, MD 20892 (Virtual Meeting).
    Contact Person: Barna Dey, Ph.D., Scientific Review Officer, 
Center for Scientific Review, National Institutes of Health, 6701 
Rockledge Drive, Room 3184, Bethesda, MD 20892, 301-451-2796, 
[email protected].

    Name of Committee: Center for Scientific Review Special Emphasis 
Panel; Member Conflict: Epidemiology, Ethical and Population 
Sciences.
    Date: November 3, 2017.
    Time: 2:30 p.m. to 4:30 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, 6701 Rockledge Drive, 
Bethesda, MD 20892 (Telephone Conference Call).
    Contact Person: Gniesha Yvonne Dinwiddie, Ph.D., Scientific 
Review Officer, Center for Scientific Review, National Institutes of 
Health, 6701 Rockledge Drive, Room 3137, Bethesda, MD 20892, 
[email protected].

    Name of Committee: Center for Scientific Review Special Emphasis 
Panel; PAR Panel: Systems Science and Health in the Behavioral and 
Social Science.
    Date: November 7, 2017.
    Time: 1:00 p.m. to 5:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, 6701 Rockledge Drive, 
Bethesda, MD 20892 (Telephone Conference Call).
    Contact Person: Ping Wu, Ph.D., Scientific Review Officer, HDM 
IRG, Center for Scientific Review, National Institutes of Health, 
6701 Rockledge Drive, Room 3166, Bethesda, MD 20892, 301-451-8428, 
[email protected].

    Name of Committee: Center for Scientific Review Special Emphasis 
Panel; PAR Panel: Improving Smoking Cessation in Socioeconomically 
Disadvantaged Populations via Scalable Interventions.
    Date: November 7, 2017.
    Time: 1:00 p.m. to 5:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, 6701 Rockledge Drive, 
Bethesda, MD 20892 (Telephone Conference Call).
    Contact Person: Kristen Prentice, Ph.D., Scientific Review 
Officer, Center for Scientific Review, National Institutes of 
Health, 6701 Rockledge Drive, Room 3112, MSC 7808, Bethesda, MD 
20892, 301-496-0726, [email protected].

    Name of Committee: Center for Scientific Review Special Emphasis 
Panel; Small Business: Digestive Sciences.
    Date: November 8-9, 2017.
    Time: 8:00 a.m. to 5:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Residence Inn Bethesda, 7335 Wisconsin Avenue, Bethesda, 
MD 20814.
    Contact Person: Martha Garcia, Ph.D., Scientific Reviewer 
Officer, Center for Scientific Review, National Institutes of 
Health, 6701 Rockledge Drive, Room 2186, MSC 7818, Bethesda, MD 
20892, 301-435-1243, [email protected].

    Name of Committee: Center for Scientific Review Special Emphasis 
Panel; Small Business: Computational, Modeling, and Biodata 
Management.
    Date: November 8, 2017.
    Time: 8:00 a.m. to 6:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Embassy Suites at the Chevy Chase Pavilion, 4300 Military 
Road NW., Washington, DC 20015.
    Contact Person: Allen Richon, Ph.D., Scientific Review Officer, 
Center for Scientific Review, National Institutes of Health, 6701 
Rockledge Drive, Room 6184, MSC 7892, Bethesda, MD 20892, 301-379-
9351, [email protected].

    Name of Committee: Center for Scientific Review Special Emphasis 
Panel; Member Conflict: Pathophysiology of Neurodevelopmental 
Disorders.
    Date: November 8, 2017.
    Time: 11:00 a.m. to 2:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, 6701 Rockledge Drive, 
Bethesda, MD 20892 (Telephone Conference Call).
    Contact Person: Boris P Sokolov, Ph.D., Scientific Review 
Officer, Center for Scientific Review, National Institutes of 
Health, 6701 Rockledge Drive, Room 5217A, MSC 7846, Bethesda, MD 
20892, 301-408-9115, [email protected].

    Name of Committee: Center for Scientific Review Special Emphasis 
Panel; PAR-17-171: Cancer Tissue Engineering Collaborative Research.
    Date: November 8, 2017.
    Time: 12:00 p.m. to 4:30 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, 6701 Rockledge Drive, 
Bethesda, MD 20892 (Virtual Meeting).

[[Page 47755]]

    Contact Person: Angela Y Ng, Ph.D., MBA, Scientific Review 
Officer, Center for Scientific Review, National Institutes of 
Health, 6701 Rockledge Drive, Room 6200, MSC 7804, Bethesda, MD 
20892, 301-435-1715, [email protected].

    Name of Committee: Center for Scientific Review Special Emphasis 
Panel; Pregnancy, Placentation, and Neonatology.
    Date: November 9, 2017.
    Time: 1:00 p.m. to 4:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, 6701 Rockledge Drive, 
Bethesda, MD 20892 (Virtual Meeting).
    Contact Person: Gary Hunnicutt, Ph.D., Scientific Review 
Officer, Center for Scientific Review, National Institutes of 
Health, 6701 Rockledge Drive, Room 6164, MSC 7892, Bethesda, MD 
20892, 301-435-0229, [email protected].

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, 
Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 
93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, 
National Institutes of Health, HHS)

    Dated: October 6, 2017.
Anna Snouffer,
Deputy Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2017-22139 Filed 10-12-17; 8:45 am]
 BILLING CODE 4140-01-P

47754 Federal Register / Vol. 82, No. 197 / Friday, October 13, 2017 / Notices polyunsaturated fatty acid accumulates property such as patentable material, Improving Smoking Cessation in in the brain during development, and and personal information concerning Socioeconomically Disadvantaged has been implicated in learning and individuals associated with the grant Populations via Scalable Interventions. Date: November 7, 2017. memory development. DEA, a applications, the disclosure of which Time: 1:00 p.m. to 5:00 p.m. metabolite derived from DHA, also has would constitute a clearly unwarranted Agenda: To review and evaluate grant been shown to accelerate neuronal invasion of personal privacy. applications. growth and development. In vitro Name of Committee: Center for Scientific Place: National Institutes of Health, 6701 studies in which neural progenitor cells Review Special Emphasis Panel; Immune Rockledge Drive, Bethesda, MD 20892 were treated with DEA derivatives System Plasticity in Dental, Oral, and (Telephone Conference Call). showed an increase in the number of Craniofacial Diseases. Contact Person: Kristen Prentice, Ph.D., Date: November 1, 2017. Scientific Review Officer, Center for somatic neurons produced after Scientific Review, National Institutes of differentiation. Time: 2:00 p.m. to 6:00 p.m. Agenda: To review and evaluate grant Health, 6701 Rockledge Drive, Room 3112, Potential Commercial Applications applications. MSC 7808, Bethesda, MD 20892, 301–496– Place: National Institutes of Health, 6701 0726, prenticekj@mail.nih.gov. • Neurogenesis, Rockledge Drive, Bethesda, MD 20892 Name of Committee: Center for Scientific • Neurite growth, (Virtual Meeting). Review Special Emphasis Panel; Small • Synaptogenesis, Contact Person: Yi-Hsin Liu, Ph.D., Business: Digestive Sciences. • Therapeutics for traumatic brain Scientific Review Officer, Center for Date: November 8–9, 2017. injury, spinal cord injury, peripheral Scientific Review, National Institutes of Time: 8:00 a.m. to 5:00 p.m. nerve injury, stroke, multiple sclerosis, Health, 6701 Rockledge Drive, Room 4214, Agenda: To review and evaluate grant autism, Alzheimer’s disease, MSC 7814, Bethesda, MD 20892, 301–435– applications. 1781, liuyh@csr.nih.gov. Place: Residence Inn Bethesda, 7335 Huntington’s disease, Parkinson’s Wisconsin Avenue, Bethesda, MD 20814. disease, and amyotrophic lateral Name of Committee: Center for Scientific Review Special Emphasis Panel; PAR–17– Contact Person: Martha Garcia, Ph.D., sclerosis. 263: Innovation for HIV Vaccine Discovery. Scientific Reviewer Officer, Center for Inventors: Erika Englund (NCATS), Date: November 3, 2017. Scientific Review, National Institutes of Juan Marugan (NCATS), Samarjit Time: 10:00 a.m. to 5:00 p.m. Health, 6701 Rockledge Drive, Room 2186, Patnaik (NCATS), Hee-Yong Kim Agenda: To review and evaluate grant MSC 7818, Bethesda, MD 20892, 301–435– (NIAAA). applications. 1243, garciamc@nih.gov. Intellectual Property: HHS Reference Place: National Institutes of Health, 6701 Name of Committee: Center for Scientific No. E–070–2012/0, U.S. Provisional Rockledge Drive, Bethesda, MD 20892 Review Special Emphasis Panel; Small (Virtual Meeting). Business: Computational, Modeling, and Patent Application 61/624,741 filed Contact Person: Barna Dey, Ph.D., Biodata Management. April 16, 2012 (expired), International Scientific Review Officer, Center for Date: November 8, 2017. Patent Application PCT/US2013/032333 Scientific Review, National Institutes of Time: 8:00 a.m. to 6:00 p.m. filed March 15, 2013 (expired), U.S. Health, 6701 Rockledge Drive, Room 3184, Agenda: To review and evaluate grant Patent 9,422,308; German Patent Bethesda, MD 20892, 301–451–2796, bdey@ applications. 602013016154.2, French Patent mail.nih.gov. Place: Embassy Suites at the Chevy Chase 2847178, and UK Patent 2847178. Name of Committee: Center for Scientific Pavilion, 4300 Military Road NW., Licensing Contact: Michael Review Special Emphasis Panel; Member Washington, DC 20015. Shmilovich, Esq, CLP; 301–435–5019; Conflict: Epidemiology, Ethical and Contact Person: Allen Richon, Ph.D., Population Sciences. Scientific Review Officer, Center for shmilovm@nih.gov. Scientific Review, National Institutes of Date: November 3, 2017. Dated: October 5, 2017. Time: 2:30 p.m. to 4:30 p.m. Health, 6701 Rockledge Drive, Room 6184, Michael Shmilovich, Agenda: To review and evaluate grant MSC 7892, Bethesda, MD 20892, 301–379– applications. 9351, allen.richon@nih.hhs.gov. Senior Licensing and Patenting Manager, Place: National Institutes of Health, 6701 Name of Committee: Center for Scientific National Heart, Lung, and Blood Institute, Rockledge Drive, Bethesda, MD 20892 Review Special Emphasis Panel; Member Office of Technology Transfer and (Telephone Conference Call). Conflict: Pathophysiology of Development . Contact Person: Gniesha Yvonne Neurodevelopmental Disorders. [FR Doc. 2017–22146 Filed 10–12–17; 8:45 am] Dinwiddie, Ph.D., Scientific Review Officer, Date: November 8, 2017. BILLING CODE 4140–01–P Center for Scientific Review, National Time: 11:00 a.m. to 2:00 p.m. Institutes of Health, 6701 Rockledge Drive, Agenda: To review and evaluate grant Room 3137, Bethesda, MD 20892, applications. DEPARTMENT OF HEALTH AND dinwiddiegy@csr.nih.gov. Place: National Institutes of Health, 6701 HUMAN SERVICES Name of Committee: Center for Scientific Rockledge Drive, Bethesda, MD 20892 Review Special Emphasis Panel; PAR Panel: (Telephone Conference Call). National Institutes of Health Systems Science and Health in the Contact Person: Boris P Sokolov, Ph.D., Behavioral and Social Science. Scientific Review Officer, Center for Center for Scientific Review; Notice of Date: November 7, 2017. Scientific Review, National Institutes of Closed Meetings Time: 1:00 p.m. to 5:00 p.m. Health, 6701 Rockledge Drive, Room 5217A, Agenda: To review and evaluate grant MSC 7846, Bethesda, MD 20892, 301–408– Pursuant to section 10(d) of the applications. 9115, bsokolov@csr.nih.gov. Federal Advisory Committee Act, as Place: National Institutes of Health, 6701 Name of Committee: Center for Scientific Rockledge Drive, Bethesda, MD 20892 asabaliauskas on DSKBBXCHB2PROD with NOTICES amended, notice is hereby given of the Review Special Emphasis Panel; PAR–17– following meetings. (Telephone Conference Call). 171: Cancer Tissue Engineering Collaborative Contact Person: Ping Wu, Ph.D., Scientific Research. The meetings will be closed to the Review Officer, HDM IRG, Center for Date: November 8, 2017. public in accordance with the Scientific Review, National Institutes of Time: 12:00 p.m. to 4:30 p.m. provisions set forth in sections Health, 6701 Rockledge Drive, Room 3166, Agenda: To review and evaluate grant 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., Bethesda, MD 20892, 301–451–8428, wup4@ applications. as amended. The grant applications and csr.nih.gov. Place: National Institutes of Health, 6701 the discussions could disclose Name of Committee: Center for Scientific Rockledge Drive, Bethesda, MD 20892 confidential trade secrets or commercial Review Special Emphasis Panel; PAR Panel: (Virtual Meeting). VerDate Sep<11>2014 19:23 Oct 12, 2017 Jkt 244001 PO 00000 Frm 00068 Fmt 4703 Sfmt 4703 E:\FR\FM\13OCN1.SGM 13OCN1

Federal Register / Vol. 82, No. 197 / Friday, October 13, 2017 / Notices 47755 Contact Person: Angela Y Ng, Ph.D., MBA, applications are filed on selected DEPARTMENT OF HEALTH AND Scientific Review Officer, Center for inventions to extend market coverage HUMAN SERVICES Scientific Review, National Institutes of for companies and may also be available Health, 6701 Rockledge Drive, Room 6200, for licensing. A description of the National Institutes of Health MSC 7804, Bethesda, MD 20892, 301–435– 1715, nga@csr.nih.gov. technology follows. National Institute of Neurological Name of Committee: Center for Scientific Small Interfering RNA Inhibition of Disorders and Stroke; Notice of Closed Review Special Emphasis Panel; Pregnancy, Cannabanoid-1 Receptor (CB1R) for Meetings Placentation, and Neonatology. Treating Type 2 Diabetes Date: November 9, 2017. Pursuant to section 10(d) of the Time: 1:00 p.m. to 4:00 p.m. Description of Technology: The Federal Advisory Committee Act, as Agenda: To review and evaluate grant invention pertains to the use of glucan amended, notice is hereby given of the applications. encapsulated non-immunostimulatory following meetings. Place: National Institutes of Health, 6701 small interfering RNAs (siRNAs) to treat The meetings will be closed to the Rockledge Drive, Bethesda, MD 20892 type-2 diabetes. Endocannabinoids (EC) public in accordance with the (Virtual Meeting). are lipid signaling molecules that act on Contact Person: Gary Hunnicutt, Ph.D., provisions set forth in sections the same cannabinoid receptors that 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., Scientific Review Officer, Center for recognize and mediate the effects of Scientific Review, National Institutes of as amended. The grant applications and endo- and phytocannabanoids. EC the discussions could disclose Health, 6701 Rockledge Drive, Room 6164, receptor CB1R activation is implicated MSC 7892, Bethesda, MD 20892, 301–435– confidential trade secrets or commercial 0229, gary.hunnicutt@nih.gov. in the development of obesity and its property such as patentable material, metabolic consequences, including (Catalogue of Federal Domestic Assistance and personal information concerning Program Nos. 93.306, Comparative Medicine; insulin resistance and type 2 diabetes. individuals associated with the grant 93.333, Clinical Research, 93.306, 93.333, Beta-cell loss has been demonstrated in applications, the disclosure of which 93.337, 93.393–93.396, 93.837–93.844, a Zucker diabetic fatty (ZDF) rat model would constitute a clearly unwarranted 93.846–93.878, 93.892, 93.893, National of type-2 diabetes through CB1R- invasion of personal privacy. Institutes of Health, HHS) mediated activation of a macrophage- mediated inflammatory response. Name of Committee: Neurological Sciences Dated: October 6, 2017. Training Initial Review Group; NST–2 Anna Snouffer, Conversely, rats treated with a Subcommittee. peripheral CB1R antagonist restores Deputy Director, Office of Federal Advisory Date: October 23, 2017. normoglycemia and preserves beta-cell Time: 8:00 a.m. to 6:00 p.m. Committee Policy. function. Similar results are seen Agenda: To review and evaluate grant [FR Doc. 2017–22139 Filed 10–12–17; 8:45 am] following selective in vivo knockdown applications. BILLING CODE 4140–01–P of macrophage CB1R by daily treatment Place: Hilton Crystal City, 2399 Jefferson of ZDF rats with the instant D-glucan- Davis Highway, Arlington, VA 22202. encapsulated CB1R Small interfering Contact Person: Elizabeth Webber, Ph.D., DEPARTMENT OF HEALTH AND RNA (siRNA). Knock-down of CB1R Scientific Review Officer, Scientific Review HUMAN SERVICES with using glucan encapsulated siRNA Branch, NINDS/NIH/DHHS, Neuroscience Center, 6001 Executive Blvd., Suite 3204, National Institutes of Health may represent a new commecializable MSC 9529, Bethesda, MD 20892–9529, (301) method of treating type-2 diabetes or 496–1917, Webbere@mail.nih.gov. Government-Owned Inventions; preventing the progression of insulin This notice is being published less than 15 Availability for Licensing resistance to overt diabetes. days prior to the meeting due to the timing Potential Commercial Applications: limitations imposed by the review and AGENCY: National Institutes of Health, Treatment of obesity, insulin resistance, funding cycle. HHS. and diabetes. Name of Committee: National Institute of ACTION: Notice. Development Stage: In vivo data Neurological Disorders and Stroke Special available. Emphasis Panel; R13 Review. SUMMARY: The inventions listed below Inventors: George Kunos, Tony Date: October 26, 2017. are owned by an agency of the U.S. Jourdan (NIAAA), Michael Czech, Time: 9:00 a.m. to 4:00 p.m. Government and are available for Myriam Aouadi. Agenda: To review and evaluate grant licensing in the U.S. Intellectual Property: HHS Reference applications. FOR FURTHER INFORMATION CONTACT: No. E–103–2013/0, U.S. Provisional Place: National Institutes of Health, Licensing information and copies of the Patent Application 61/839,239 filed Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 (Virtual patent applications listed below may be June 25, 2013, International Patent Meeting). obtained by emailing the indicated Application PCT/US2014/043924 filed Contact Person: Ernie Lyons, Ph.D., licensing contact at the National Heart, June 24, 2014, European Patent Scientific Review Officer, Scientific Review Lung, and Blood, Office of Technology Application 14818342.9 filed June 24, Branch, NINDS/NIH/DHHS, Neuroscience Transfer and Development Office of 2014 and U.S. Patent Application 14/ Center, 6001 Executive Blvd., Suite 3204, Technology Transfer, 31 Center Drive 900,951 filed June 24, 2014. MSC 9529, Bethesda, MD 20892–9529, (301) Room 4A29, MSC2479, Bethesda, MD Licensing Contact: Michael 496–4056, lyonse@ninds.nih.gov. 20892–2479; telephone: 301–402–5579. Shmilovich, Esq, CLP; 301–435–5019; This notice is being published less than 15 A signed Confidential Disclosure shmilovm@nih.gov. days prior to the meeting due to the timing asabaliauskas on DSKBBXCHB2PROD with NOTICES Agreement may be required to receive Dated: October 5, 2017. limitations imposed by the review and copies of the patent applications. funding cycle. Michael Shmilovich, SUPPLEMENTARY INFORMATION: This Name of Committee: National Institute of Senior Licensing and Patenting Manager, Neurological Disorders and Stroke Special notice is in accordance with 35 U.S.C. National Heart, Lung, and Blood Institute, Emphasis Panel; F32 and K22 Review. 209 and 37 CFR part 404 to achieve Office of Technology Transfer and Date: November 2–3, 2017. commercialization of results of Development. Time: 8:00 a.m. to 12:00 p.m. federally-funded research and [FR Doc. 2017–22147 Filed 10–12–17; 8:45 am] Agenda: To review and evaluate grant development. Foreign patent BILLING CODE 4140–01–P applications. VerDate Sep<11>2014 18:05 Oct 12, 2017 Jkt 244001 PO 00000 Frm 00069 Fmt 4703 Sfmt 4703 E:\FR\FM\13OCN1.SGM 13OCN1


Document Created: 2017-10-13 04:33:37
Document Modified: 2017-10-13 04:33:37
CategoryRegulatory Information
CollectionFederal Register
sudoc ClassAE 2.7:
GS 4.107:
AE 2.106:
PublisherOffice of the Federal Register, National Archives and Records Administration
SectionNotices
DatesNovember 1, 2017.
FR Citation82 FR 47754 
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR